| Outcome Measures: |
Primary: Changes from baseline to post-treatment in composition in gut microbiota analyzed by meta-genome sequencing., Baseline, Week 4, Week 8, Week 12|Changes from baseline to post-treatment in composition in fasting blood glucose., Baseline, Week 4, Week 8, Week 12|Changes from baseline to post-treatment in composition in level of TNF-a., Baseline, Week 4, Week 8, Week 12|Changes from baseline to post-treatment in composition in fasting insulin., Baseline, Week 4, Week 8, Week 12|Changes from baseline to post-treatment in blood lipid including cholesterol, triglycerides, high-density lipoprotein., Baseline, Week 4, Week 8, Week 12|Changes from baseline to post-treatment in composition in 2-hour postprandial blood glucose., Baseline, Week 4, Week 8, Week 12|Changes from baseline to post-treatment in composition in level of IL-6., Baseline, Week 4, Week 8, Week 12|Changes from baseline to post-treatment in composition in level of IL-8., Baseline, Week 4, Week 8, Week 12|Changes from baseline to post-treatment in composition in level of IL-10., Baseline, Week 4, Week 8, Week 12|Changes from baseline to post-treatment in composition in level of C-reative protein., Baseline, Week 4, Week 8, Week 12 | Secondary: The linear relationship between gut microbiota and blood glucose and blood lipid level., Week 4, Week 8, Week 12|The linear relationship between gut microbiota and inflammation factors level., Week 4, Week 8, Week 12
|
